If you work with patients who struggle with obesity, you’ve probably felt it. Our entire approach to weight and metabolic health is shifting. And now, the World Health Organization has made it official by releasing its first ever global guideline on GLP-1 medications like semaglutide, liraglutide, and tirzepatide.
This isn’t just another policy update. For many of us, it marks a turning point in how the world views and treats obesity as a chronic, lifelong disease. But what does this mean for many of us on the ground?
Why This Moment Matters
Obesity affects over a billion people worldwide. In 2024 alone, it contributed to 3.7 million deaths. Beyond the human cost, it strains healthcare systems, drives up rates of diabetes and cardiovascular disease, and impacts nearly every aspect of public health.
And if global trends continue, those numbers will only climb. Fast.
The WHO’s message is clear: obesity care can’t be reduced to a prescription. It requires a long-term, whole-person, whole-system approach.
What the Guideline Actually Says
A few key takeaways stand out:
1. GLP-1s can be used long-term in adults with obesity (with the exception of pregnancy).
The data supports meaningful weight reduction and metabolic benefits, but this is still a conditional recommendation. We’re missing long-term safety data, real-world affordability insights, and a clear picture of how health systems will sustain widespread use.
2. Behavioral interventions remain non-negotiable.
The WHO isn’t softening its stance here: GLP-1s should always be paired with structured nutrition and physical activity support. Even with limited evidence, combined approaches consistently show better outcomes.
In short medication can help, but it’s not the whole treatment plan.
A Call to Rethink Our Approach
The guideline nudges all of us (physicians, pharmacists, nurses, dietitians, health coaches) to zoom out and consider the bigger picture.
Effective obesity care must also include:
- Public policies that make healthy choices easier, not harder
- Early, structured support for people at risk
- Systems designed to provide lifelong, equitable access, not one-off solutions
It’s worth asking, are our current systems built for this kind of care and are we, individually, prepared to deliver it?
Important Cautions
The WHO doesn’t shy away from the challenges ahead:
Access & equity
Even with expanded manufacturing, fewer than 10% of eligible patients may access GLP-1s by 2030. The WHO suggests pooled procurement and tiered pricing to avoid deepening global health disparities.
Quality & safety
High demand has fueled a dangerous rise in counterfeit and substandard products. Providers must rely on regulated sources and actively educate patients on what “safe access” really means.
Long-term management
Obesity is a chronic, relapsing condition. GLP-1s are tools, not cures. Patients will still need long-term follow-up, behavioral support, and realistic expectations.
So What Now?
This new guidance invites us to pause and reflect:
- How can we integrate these recommendations into everyday practice?
- How do we help patients understand that obesity care is a journey, not a 12 week plan?
- What system level changes need to happen so we’re not just treating individuals but improving population health?
Here are a few places to start:
- Have deeper, more holistic conversations with patients about sleep, stress, movement, nutrition, and mental health.
- Advocate for coverage and access, especially for underserved communities.
- Stay current as new evidence emerges around long-term use, cycling, discontinuation, and patient reported outcomes.
Your Turn
How do you see these recommendations shaping your practice?
What challenges or opportunities do you anticipate as this guidance becomes part of global obesity care?
Let’s keep the conversation going. These guidelines are just the beginning; the real transformation happens in our clinics, our pharmacies, and our daily interactions with patients.
References
World Health Organization. (2025, December 1). WHO issues global guideline on the use of GLP-1 medicines in treating obesity. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
World Health Organization. (2024). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
World Health Organization. (2024). Global report on obesity: Accelerating action to stop obesity. https://www.who.int/publications/i/item/9789240075766
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., … & Rosenstock, J. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
